Basic information Description Indications and Usage Mechanisms of Action Clinical Research Warnings and Precautions Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Blood System Drugs >  Anticoagulant and Antiplatelet Drugs >  Dabigatran etexilate

Dabigatran etexilate

Basic information Description Indications and Usage Mechanisms of Action Clinical Research Warnings and Precautions Safety Related Supplier
Dabigatran etexilate Basic information
Dabigatran etexilate Chemical Properties
  • Melting point:128-129°
  • Density 1.24±0.1 g/cm3(Predicted)
  • storage temp. Sealed in dry,Store in freezer, under -20°C
  • pka9.88±0.46(Predicted)
Dabigatran etexilate Usage And Synthesis
  • Description

    Dabigatran etexilate (Pradaxa, BIBR 1048, Boehringer Ingelheim) is the prodrug of dabigatran (originally known as BIBR 953), a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.

  • Indications and UsageDabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease.
  • Mechanisms of ActionIt achieves anticoagulant effects through specific and selective inhibition of blood enzymes (free or bound). After oral ingestion and absorption through the digestive system, Dabigatran turns into Dabiga groups that have the direct anticoagulant abilities. By binding to thrombin in fibrin specific binding sites, Dabigatran stops fibrinogen from cleaving into fibrin, thus interrupting the blood clotting network and consequently thrombosis. Dabiga groups can also dissociate from the fibrin-thrombin coagulate and have an anticoagulating effect. Different from vitamin K antagonists, which affect different coagulants, Dabigatran can provide effective, predictable and stable anticoagulant effects. It will also have minimal reactions to other drugs or food, and does not require frequent monitoring or dosage adjustment.
  • Clinical ResearchCompared to the control group treated with Warfarin, Dabigatran can significantly decrease the risk of stroke and embolic disease (including hemorrhagic stroke), greatly reduce the occurrence of bleeding (including fatal bleeding and intracranial hemorrhage), and greatly lower vascular mortality rate. Dabigatran provides effective and stable anticoagulant effects and does not require constant monitoring of anticoagulant functions or dosage adjustments.
  • Warnings and Precautions1. Dabigatran is not to be used by patients with severe kidney damage (CrCl<30ml/min).
    2. Patients with high bleeding risk should also not use Dabigatran.
    3. Patients must be tested and monitored for signs of lack of bleeding or anemia; if there is severe bleeding, cease use of Dabigatran and identify the bleeding area.
    4. Dabigatran is not suitable for patients with significant manifestations of rheumatic valvar heart disease or patients with artificial heart valves.
  • DescriptionDabigatran etexilate is an orally administered pro-drug of dabigatran, which is a direct inhibitor of thrombin and a potent anticoagulant. The serine protease thrombin is the final mediator in the coagulation cascade that leads to the production of fibrin, the main protein component of blood clots. Thrombin is also a potent activator of platelets. Consequently, thrombin inhibitors have found utility as anticoagulants in treating arterial and venous thrombosis. Warfarin, although orally available, has a narrow therapeutic index and requires frequent monitoring and dosage adjustment. Low-molecular-weight heparins provide better safety profile and less inter-patient variability; however, these agents are only available for parenteral administration. Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that act by directly binding to thrombin at its catalytic or fibrinogen-binding sites, or both. Unlike the heparins, DTIs do not require the activation of secondary factors such as antithrombin to derive their activity, which makes their action more predictable. In addition, their ability to inhibit both free and clot-bound thrombin predisposes them for enhanced anticoagulation effect.
  • OriginatorBoehringer Ingelheim (Germany)
  • UsesBIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner sin
  • DefinitionChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.
  • brand namePradaxa
  • Chemical SynthesisThe chemical synthesis of dabigatran etexilate starts with the acylation of ethyl 3-(2-pyridylamino)propionate with 4-(methylamino)-3-nitrobenzoyl chloride to produce the corresponding amide. Subsequent reduction of the nitro group by catalytic hydrogenation, and cyclization of the resultant phenylenediamine with N-(4-cyanophenyl)glycine leads to a benzimidazole intermediate. The cyano group is then transformed into an amidine by employing the Pinner reaction. Finally, acylation of the amidino group with hexyl chloroformate gives rise to dabigatran etexilate.
Dabigatran etexilate(211915-06-9)Related Product Information
Dabigatran etexilateSupplierMore
  • Company Name:Beijing Lianben Pharm-Chemicals Tech. Co., Ltd Gold
  • Tel:+86-10-83386766
  • Company Name:Changzhou Rongen Yiyao Co.LTD Gold
  • Tel:0519-85286996 18261185267
  • Company Name:Jinan Jianfeng Chemical Co., Ltd. Gold
  • Tel:0531-88110457-
  • Company Name:Guangzhou Dreampharm Biotechnology Co., Ltd. Gold
  • Tel:17825480238
  • Company Name:Changzhou SYM Tech. Co.,Ltd. Gold
  • Tel:17327200503 519-88712001-
Related articles